CA-ADVA
24.1.2023 18:01:38 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Brandywine Communications is using its OSA 5422 grandmaster clock to deliver a robust and feature-rich M-Code timing solution for use cases such as US Department of Defense applications. The new edge synchronization offering addresses the key requirements of military networks by providing enhanced positioning, navigation and timing (PNT) capabilities and improved resilience. Built on Oscilloquartz’s versatile timing technology with integrated M-Code capabilities, the solution is ideal for the most demanding military edge applications. It supports 1Gbit/s and 10Gbit/s interfaces, provides innovative GNSS assurance capabilities as well as backup through Oscilloquartz’s assured PNT (aPNT+™) technology, and meets the most stringent timing demands in an operationally efficient and cost-effective way.
“Our M-Code edge timing offering will be a game-changer for defense applications. Powered by ADVA’s OSA 5422 grandmaster clock, it meets the most urgent needs of military networks that require precise and reliable PNT information and delivers new levels of reliability and security. One key feature of the OSA 5422 is its long holdover and PTP backup, which enables it to maintain accurate timing even in the event of M-Code disruption. This is critical for pressurized defense networks that need to operate in a variety of difficult environments,” said Allen Ronk, president of Brandywine Communications. “Our solution features multi-source backup capabilities to ensure that M-Code outages do not disrupt synchronization. It also provides sync assurance capabilities that continually monitor the performance of the timing system and take immediate corrective action when needed.”
M-Code is an encrypted GPS signal used exclusively by the US military in defense applications that require precise and reliable synchronization. Resistant to jamming and spoofing, M-Code is an invaluable asset for defense organizations operating in challenging conditions. ADVA’s OSA 5422 grandmaster clock is now integrated with a highly reliable M-Code receiver that meets stringent frequency and phase synchronization needs and offers the best holdover performance of any edge device on the market. Also equipped with multi-band, multi-constellation GNSS receivers for when M-Code is not available, the device offers support for legacy interfaces such as BITS and IRIG, and features eight field-upgradeable 10Gbit/s ports and 1Gbit/s interfaces. The OSA 5422 is also environmentally hardened with hot-swappable modules and power supplies for easy field upgrades.
“As military applications demand increasingly precise and reliable PNT capabilities, the need for secure, jamming- and spoofing-resistant M-Code technology becomes ever more pressing. With its long holdover, multi-source backup capabilities, sync assurance capabilities, and other advanced features, our OSA 5422 is perfectly positioned to meet this demand,” commented Gil Biran, GM of Oscilloquartz, ADVA. “We’re excited to be working with Brandywine Communications as our strategic partner and to be bringing our innovation to defense applications that rely on precise and reliable PNT in the US and elsewhere. The market for military GPS receivers with M-Code capabilities is growing, as defense organizations seek to enhance their PNT capabilities and improve resilience. Together, we’re helping empower a whole new section of customers to benefit from the industry’s most agile synchronization toolkit.”
ADVA’s Oscilloquartz aPNT+™ and M-Code technology is being showcased at the Precise Time and Time Interval Systems and Applications Meeting (PTTI 2023) in Long Beach, California, from January 23 to 26. Attendees can visit the Oscilloquartz team at Brandywine Communications’ booth to learn about the platform’s ability to provide resilient and assured PNT services for military applications in line with the Department of Defense’s latest zero-trust strategy, and how the OSA 5422 supports both time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS).
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005723/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
